{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:44:07Z","timestamp":1740159847386,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"R\u00e9seau M\u00e8re-Enfant de la Francophonie"},{"DOI":"10.13039\/501100024252","name":"Facult\u00e9 de pharmacie, Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024252","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R\u00e9seau de recherche en Sant\u00e9 Respiratoire du Qu\u00e9bec"},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13318-024-00913-4","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:04:08Z","timestamp":1726473848000},"page":"677-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vancomycin in Pediatric Patients with Cystic Fibrosis: Dose Optimization Using Population Pharmacokinetic Approach"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0447-7668","authenticated-orcid":false,"given":"Aysenur","family":"Yaliniz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Blouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-\u00c9laine","family":"M\u00e9tras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christine","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Autmizguine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Marsot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"1","key":"913_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1891\/NN-2022-0007","volume":"42","author":"H Myer","year":"2023","unstructured":"Myer H, Chupita S, Jnah A. Cystic fibrosis: back to the basics. Neonatal Netw. 2023;42(1):23\u201330.","journal-title":"Neonatal Netw"},{"issue":"21","key":"913_CR2","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1001\/jama.2023.8120","volume":"329","author":"T Ong","year":"2023","unstructured":"Ong T, Ramsey BW. Cystic fibrosis: a review. Jama. 2023;329(21):1859\u201371.","journal-title":"Jama."},{"key":"913_CR3","volume-title":"The canadian cystic fibrosis registry 2021 Annual Data Report","author":"C Cf","year":"2023","unstructured":"Cf C. The canadian cystic fibrosis registry 2021 Annual Data Report. Toronto: Canada; 2023."},{"issue":"11","key":"913_CR4","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1002\/ppul.26641","volume":"58","author":"J Kim","year":"2023","unstructured":"Kim J, Lyman B, Savant AP. Cystic fibrosis year in review 2022. Pediatr Pulmonol. 2023;58(11):3013\u201322.","journal-title":"Pediatr Pulmonol."},{"issue":"2","key":"913_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4187\/respcare.06697","volume":"65","author":"T Nl","year":"2020","unstructured":"Nl T. Cystic fibrosis lung disease: an overview. Respir Care. 2020;65(2):233\u201351.","journal-title":"Respir Care"},{"key":"913_CR6","doi-asserted-by":"crossref","unstructured":"Ciuca IM, Dediu M, Popin D, Pop Ll, Tamas LA, Pilut CN, et al. Antibiotherapy in children with cystic fibrosis-an extensive review. Children (Basel). 2022;9(8):1258.","DOI":"10.3390\/children9081258"},{"issue":"11","key":"913_CR7","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","volume":"77","author":"J Mn","year":"2017","unstructured":"Mn J. The whole price of vancomycin: toxicities, troughs,and time. Drugs. 2017;77(11):1143\u201354.","journal-title":"Drugs."},{"key":"913_CR8","doi-asserted-by":"crossref","unstructured":"Zamoner W, Prado IRS, Balbi Al, Ponce D. Vancomycin dosing, monitoring and toxicity: critical review of the clinical practice. Clin Exp Pharmacol Physiol. 2019;46(4):292\u2013301.","DOI":"10.1111\/1440-1681.13066"},{"issue":"1","key":"913_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40262-021-01050-w","volume":"61","author":"A Aljutayli","year":"2022","unstructured":"Aljutayli A, El-Haffaf I, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, Part II: in pediatric patients. Clin Pharmacokinet. 2022;61(1):47\u201370.","journal-title":"Clin Pharmacokinet."},{"issue":"8","key":"913_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00228-023-03511-6","volume":"79","author":"S Wei","year":"2023","unstructured":"Wei S, Chen J, Zhao Z, Mei S. External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients. Eur J Clin Pharmacol. 2023;79(8):1031\u201342.","journal-title":"Eur J Clin Pharmacol"},{"key":"913_CR11","doi-asserted-by":"crossref","unstructured":"Epps QJ, Epps Kl, Young DC, Zobell JT. State of the art in cystic fibrosis pharmacology-optimization of antimicrobials in the treatment of cystic Fibrosis pulmonary exacerbations: I. Anti-methicillin-resistant Staphylococcus aureus (Mrsa) antibiotics. Pediatr Pulmonol. 2020;55(1):33\u201357.","DOI":"10.1002\/ppul.24537"},{"issue":"2","key":"913_CR12","first-page":"155","volume":"21","author":"M Ej","year":"2016","unstructured":"Ej M, Jl H, Sp M, Cj B. Evaluation of vancomycin dosing in pediatric cystic fibrosis patients. J Pediatr Pharmacol Ther. 2016;21(2):155\u201361.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"913_CR13","doi-asserted-by":"publisher","first-page":"E00420","DOI":"10.1002\/prp2.420","volume":"6","author":"JF Monteiro","year":"2018","unstructured":"Monteiro JF, Hahn SR, Gon\u00e7alves J, Fresco P. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect. 2018;6(4):E00420.","journal-title":"Pharmacol Res Perspect."},{"issue":"1","key":"913_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the american society of health-system pharmacists, the infectious diseases society of america, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Health Syst Pharm."},{"issue":"11","key":"913_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review by The American Society of health-system pharmacists, The infectious diseases society of America, The pediatric infectious diseases society, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm."},{"issue":"9","key":"913_CR16","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1093\/jac\/dkab048","volume":"76","author":"SCJ Jorgensen","year":"2021","unstructured":"Jorgensen SCJ, Dersch-Mills D, Timberlake K, Stewart JJ, Gin A, Dresser LD, et al. Aucs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. J Antimicrob Chemother. 2021;76(9):2237\u201351.","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"913_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/jcph.1323","volume":"59","author":"C Stockmann","year":"2019","unstructured":"Stockmann C, Olson J, Rashid J, Lubsch L, Young DC, Hersh AL, et al. An evaluation of vancomycin area under the curve estimation methods for children treated for acute pulmonary exacerbations of cystic fibrosis due to methicillin-resistant Staphylococcus aureus. J Clin Pharmacol. 2019;59(2):198\u2013205.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"913_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"B Hk","year":"2015","unstructured":"Hk B, Jf M. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395\u2013404.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"913_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","volume":"7","author":"RJ Keizer","year":"2018","unstructured":"Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-informed precision dosing at the bedside: scientific challenges and opportunities. Cpt Pharmacometrics Syst Pharmacol. 2018;7(12):785\u20137.","journal-title":"Cpt Pharmacometrics Syst Pharmacol."},{"issue":"4","key":"913_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-023-01233-7","volume":"62","author":"M El Hassani","year":"2023","unstructured":"El Hassani M, Marsot A. External evaluation of population pharmacokinetic models for precision dosing: current state and knowledge gaps. Clin Pharmacokinet. 2023;62(4):533\u201340.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"913_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40262-020-00937-4","volume":"60","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Wang CY, Li ZR, Pan Y, Liu MB, Jiao Z. Can population pharmacokinetics of antibiotics be extrapolated? Implications of external evaluations. Clin Pharmacokinet. 2021;60(1):53\u201368.","journal-title":"Clin Pharmacokinet."},{"issue":"8","key":"913_CR22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40262-021-01027-9","volume":"60","author":"E Chung","year":"2021","unstructured":"Chung E, Sen J, Patel P, Seto W. Population pharmacokinetic models of vancomycin in paediatric patients: a systematic review. Clin Pharmacokinet. 2021;60(8):985\u20131001.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"913_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/bja\/aex007","volume":"118","author":"M Hara","year":"2017","unstructured":"Hara M, Masui K, Eleveld DJ, Struys M, Uchida O. Predictive performance of eleven pharmacokinetic models for propofol infusion in children for long-duration anaesthesia. Br J Anaesth. 2017;118(3):415\u201323.","journal-title":"Br J Anaesth."},{"issue":"2","key":"913_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. Cpt Pharmacometrics Syst Pharmacol. 2017;6(2):87\u2013109.","journal-title":"Cpt Pharmacometrics Syst Pharmacol."},{"issue":"12","key":"913_CR25","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1002\/phar.1320","volume":"33","author":"C Stockmann","year":"2013","unstructured":"Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, et al. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy. 2013;33(12):1288\u201396.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"913_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40262-020-00866-2","volume":"59","author":"A Aljutayli","year":"2020","unstructured":"Aljutayli A, Marsot A, Nekka F. An update on population pharmacokinetic analyses of vancomycin, Part I: in adults. Clin Pharmacokinet. 2020;59(6):671\u201398.","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"913_CR27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FTD.0000000000000318","volume":"38","author":"R Guilhaumou","year":"2016","unstructured":"Guilhaumou R, Marsot A, Dupouey J, Galambrun C, Boulamery A, Coze C, et al. Pediatric patients with solid or hematological tumor disease: vancomycin population pharmacokinetics and dosage optimization. Ther Drug Monit. 2016;38(5):559\u201366.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"913_CR28","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/1078155215591386","volume":"22","author":"O Abdel Hadi","year":"2016","unstructured":"Abdel Hadi O, Al Omar S, Nazer Lh, Mubarak S, Le J. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients. J Oncol Pharm Pract. 2016;22(3):448\u201353.","journal-title":"J Oncol Pharm Pract"},{"key":"913_CR29","doi-asserted-by":"crossref","unstructured":"Le J, Capparelli EV, Wahid U, Wu YS, Romanowski Gl, Tran TM, et al. Bayesian estimation of vancomycin pharmacokinetics in obese children: matched case-control study. Clin Ther. 2015;37(6):1340\u201351.","DOI":"10.1016\/j.clinthera.2015.05.006"},{"issue":"1","key":"913_CR30","first-page":"1017","volume":"2","author":"J Le","year":"2014","unstructured":"Le J, Vaida F, Nguyen E, Adler-Shohet FC, Romanowski G, Kim J, et al. Population-based pharmacokinetic modeling of vancomycin in children with renal insufficiency. J Pharmacol Clin Toxicol. 2014;2(1):1017\u201326.","journal-title":"J Pharmacol Clin Toxicol."},{"issue":"5","key":"913_CR31","first-page":"616","volume":"45","author":"A Duong","year":"2023","unstructured":"Duong A, Simard C, Williamson D, Marsot A. Tobramycin A priori dosing regimens based on poppk model simulations in critically ill patients: are they transferable? Ther Drug Monit. 2023;45(5):616\u201322.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"913_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.21037\/atm-22-236","volume":"10","author":"N Chen","year":"2022","unstructured":"Chen N, Guo J, Xie J, Xu M, Hao X, Ma K, et al. Population pharmacokinetics of polymyxin b: a systematic review. Ann Transl Med. 2022;10(4):231.","journal-title":"Ann Transl Med."},{"issue":"9","key":"913_CR33","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00228-022-03359-2","volume":"78","author":"W Huang","year":"2022","unstructured":"Huang W, Zheng Y, Huang H, Cheng Y, Liu M, Chaphekar N, et al. External evaluation of population pharmacokinetic models for voriconazole in chinese adult patients with hematological malignancy. Eur J Clin Pharmacol. 2022;78(9):1447\u201357.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"913_CR34","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/heartjnl-2011-301247","volume":"98","author":"KG Moons","year":"2012","unstructured":"Moons KG, Kengne AP, Grobbee DE, Royston P, Vergouwe Y, Altman DG, et al. Risk prediction models: Ii. external validation, model updating, and impact assessment. Heart. 2012;98(9):691\u20138.","journal-title":"Heart."},{"issue":"1","key":"913_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13318-021-00730-z","volume":"47","author":"OO Akunne","year":"2022","unstructured":"Akunne OO, Mugabo P, Argent AC. Pharmacokinetics of vancomycin in critically Ill children: a systematic review. Eur J Drug Metab Pharmacokinet. 2022;47(1):31\u201348.","journal-title":"Eur J Drug Metab Pharmacokinet."},{"issue":"4","key":"913_CR36","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/j.1365-2125.2012.04406.x","volume":"75","author":"W Zhao","year":"2013","unstructured":"Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2013;75(4):1068\u201380.","journal-title":"Br J Clin Pharmacol."},{"key":"913_CR37","unstructured":"Canada CF (2021) Antibiotic dosing guideline for cystic fibrosis. https:\/\/www.cysticfibrosis.ca\/uploads\/antibiotic%20dosing%20guideline%20aug%202021.Pdf. Date Accessed: 29 Nov 2023."},{"issue":"1","key":"913_CR38","first-page":"63","volume":"28","author":"TA Imburgia","year":"2023","unstructured":"Imburgia TA, Seagren RM, Christensen H, Lasarev MR, Bogenschutz MC. Review of tobramycin dosing in pediatric patients with cystic fibrosis. J Pediatr Pharmacol Ther. 2023;28(1):63\u201370.","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"11","key":"913_CR39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ppul.22813","volume":"48","author":"DC Young","year":"2013","unstructured":"Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. aminoglycosides. Pediatr Pulmonol. 2013;48(11):1047\u201361.","journal-title":"Pediatr Pulmonol."},{"key":"913_CR40","doi-asserted-by":"crossref","unstructured":"Le J, Bradley JS, Murray W, Romanowski Gl, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):155\u2013163.","DOI":"10.1097\/INF.0b013e318286378e"},{"issue":"4","key":"913_CR41","doi-asserted-by":"publisher","first-page":"E109","DOI":"10.1093\/jpids\/piu110","volume":"4","author":"J Le","year":"2015","unstructured":"Le J, Ny P, Capparelli E, Lane J, Ngu B, Muus R, et al. Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children. J Pediatric Infect Dis Soc. 2015;4(4):E109\u201316.","journal-title":"J Pediatric Infect Dis Soc."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00913-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00913-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00913-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:10:36Z","timestamp":1731071436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00913-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00913-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"7 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Aysenur Yaliniz, Mathieu Blouin, Marie-\u00c9laine M\u00e9tras, Marie-Christine Boulanger, Karine Cloutier, Marie-H\u00e9l\u00e8ne Dub\u00e9, Julie Autmizguine and Am\u00e9lie Marsot declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki declaration (and its amendments). The study was approved by the academic ethic committee of Universit\u00e9 de Montr\u00e9al on March 2, 2021 (CERC-21-033-R). The multicentric research protocol was previously approved (MP-21-2021-3329) by the Centre Hospitalier Universitaire Sainte-Justine\u2019s ethics committees on June 8, 2022 and certified via an institutional feasibility review (MEO-21-2023-6385) by the Centre M\u00e8re-Enfant-Soleil du CHU de Qu\u00e9bec-Universit\u00e9 Laval. Preliminary results were presented at five scientific meetings from December 2022 to January 2024. Four of these meetings were held locally in Quebec, Canada, while one took place internationally in Oslo, Norway. The latter was the 21st edition of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology\u2019s congress and the presentation was titled: Use of vancomycin population pharmacokinetic model in pediatric patients with cystic fibrosis: impact of data on the predictive performance.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Authorization to access patient records has been obtained from the Centre Hospitalier Universitaire Sainte-Justine and Centre M\u00e8re-Enfant-Soleil du CHU de Qu\u00e9bec-Universit\u00e9 Laval. Since the data were collected retrospectively and anonymously, individual informed consent from the participants was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}